Phencyclidine

Gabather reports initial positive results from the EEG/fMRI target engagement study

Retrieved on: 
Thursday, March 7, 2024
Anxiety, SAD, GABAA, Benzodiazepine, Ketamine, Deficit spending, Schizophrenia, BZD, Dog, Rat, PAM, Learning, Relaxation, Safety, Phencyclidine, Attention, Alpha, Memory, EEG, Patient, DSM-IV codes, Social, Lorazepam, Mouse, Brain, Medical imaging

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Key Points: 
  • STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.
  • The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002.
  • The secondary objective to demonstrate target engagement in human brain was also met.
  • The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders.

Gabather reports initial positive results from the EEG/fMRI target engagement study

Retrieved on: 
Thursday, March 7, 2024
Anxiety, SAD, GABAA, Benzodiazepine, Ketamine, Deficit spending, Schizophrenia, BZD, Dog, Rat, PAM, Learning, Relaxation, Safety, Phencyclidine, Attention, Alpha, Memory, EEG, Patient, DSM-IV codes, Social, Lorazepam, Mouse, Brain, Medical imaging

STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.

Key Points: 
  • STOCKHOLM, March 7, 2024 /PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) today reports initial positive results from the EEG/fMRI target engagement study, a double-blinded placebo-controlled, cross-over phase Ib study of Gabather's GABAA-receptor positive allosteric modulator, GT-002, in healthy volunteers.
  • The study met the primary objective to confirm a favourable safety and tolerability profile of GT-002.
  • The secondary objective to demonstrate target engagement in human brain was also met.
  • The study clearly demonstrated that GT-002 is safe and well tolerated at dose levels expected to be effective for treatment of patients with neuropsychiatric disorders.

Psychedelic Drugs Global Market Report 2022: Featuring Key Players Johnson & Johnson, Pfizer, Hikma Pharmaceuticals & Others - ResearchAndMarkets.com

Retrieved on: 
Friday, August 5, 2022
Mental Health, Arts, Museums, Entertainment, Other Health, Alternative Medicine, Managed Care, Music, General Health, Pharmaceutical, Health, Opioid, Depression, Johnson & Johnson, Hallucinogen, Lysergic acid diethylamide, Salvia, National Alliance on Mental Illness, Growth, Brain, Behavior, Plant, Perception, Narcolepsy, Patient, Lists of diseases, National Alliance, GHB, LSD, Panic, Mental disorder, Post-traumatic stress disorder, Esketamine, Thought, Pharmacy, PTSD, Gamma-Hydroxybutyric acid, Mental, NAMI, Organization, Pharmaceutical industry, Medicine, Ketamine, Phencyclidine

The "Psychedelic Drugs Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Psychedelic Drugs Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • These drugs are a group of substances that usually alter and enhance perception, thinking processes, energy levels, and promote mental experiences.
  • Major companies operating in the psychedelic drug market are introducing nasal-spray drugs for major depressive disorders to sustain their position in the market.
  • For instance, in March 2019, Johnson & Johnson, a US-based company that manufactures psychedelic drugs and pharma medicines, launched a new depression spray named Spravato.

Why the North America Psychedelic Drugs Market is Expected to Grow With the Fastest CAGR for Next Several Years

Retrieved on: 
Tuesday, June 8, 2021
Psychoactive drugs, Drugs, Hallucinations, Stimulants, Hallucinogen, Dissociative, Dissociative drugs, Euphoriants, Lysergic acid diethylamide, Psychedelic drug, Phencyclidine, Empathogen–entactogen

Psychedelic drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.

Key Points: 
  • Psychedelic drugs have the ability to change or enhance the sensory perceptions, thought processes, energy levels and have also been reported to facilitate spiritual experiences.
  • Psychedelic drugs can be categorized into empathogens and dissociative drugs (such as PCP) and serotonergic (classic hallucinogens) such as LSD.
  • A r eport from Data Bridge Market Research projected that the psychedelic drugs market is expected to gain market growth in the forecast period of 2021 to 2028.
  • Data Bridge Market Research analyses that the market is growing with a CAGR of 11.5% in the forecast period of 2021 to 2028 and is expected to reach USD 6,433.94 Million by 2028.

Priority Health launches virtual-first coverage option with new MyPriority Telehealth PCP plans

Retrieved on: 
Wednesday, October 21, 2020
General Health, Internet, Health, Technology, Telecommunications, Articles, Health, Health informatics, Telemedicine, Assistive technology, Telehealth, eHealth, Primary care physician, PCP, Phencyclidine

Priority Health announced today the launch of their new MyPriority Telehealth PCP plans that will go into effect on January 1, 2021.

Key Points: 
  • Priority Health announced today the launch of their new MyPriority Telehealth PCP plans that will go into effect on January 1, 2021.
  • The new plans are designed for consumers who are seeking health coverage that is virtual-first and are comfortable with online interactions with providers.
  • Members who choose one of the MyPriority Telehealth PCP plans will have a doctor assigned as their primary care physician (PCP) through Doctor on Demand and all visits will take place virtually.
  • For more information on Priority Health or MyPriority plan options, visit mypriority.com or call an enrollment specialist at 833.412.1208.